Table I.
Patient Demographics and Baseline Characteristics for the Intent‐to‐Treat Cohort*
| Olmesartan Medoxomil (n=199) | Losartan Potassium (n=200) | Valsartan (n=197) | Placebo (n=100) | |
|---|---|---|---|---|
| Mean age, y (SD) | 52.2 (9.6) | 51.3 (10.5) | 52.2 (10.3) | 52.4 (10.0) |
| Patients ≤65 y, % | 92.0 | 92.5 | 88.8 | 89.0 |
| Race, % | ||||
| White | 63.3 | 62.5 | 65.0 | 65.0 |
| Black | 22.1 | 23.5 | 18.8 | 22.0 |
| Asian | 1.5 | 2.5 | 1.5 | 2.0 |
| Hispanic | 13.1 | 10.5 | 14.2 | 11.0 |
| Other | 0 | 1.0 | 0.5 | 0 |
| Men, % | 62.8 | 60.5 | 66.0 | 52.0 |
| Mean baseline SeSBP, mm Hg (SD) | 155.4 (11.2) | 155.0 (11.5) | 154.3 (10.6) | 153.9 (11.0) |
| Mean baseline SeDBP, mm Hg (SD) | 103.5 (3.1) | 103.6 (2.8) | 103.3 (3.2) | 103.2 (2.8) |
| Mean duration of HTN, y (SD) | 8.5 (8.3) | 8.9 (8.7) | 10.4 (9.7) | 9.0 (8.4) |
| Family history of HTN, % | 71.9 | 65.5 | 65.5 | 70.0 |
| Antihypertensive use in past 90 days, % | 82.9 | 78.0 | 80.2 | 83.0 |
| NSAID use, No. (%)† | ||||
| Indomethacin | 0 | 1 (0.5) | 0 | 5 (4.7) |
| Celecoxib | 4 (1.9) | 10 (4.8) | 4 (2.0) | 3 (2.8) |
| Rofecoxib | 6 (2.9) | 8 (3.9) | 5 (2.5) | 1 (0.9) |
| Ibuprofen | 32 (15.5) | 38 (18.4) | 31 (15.3) | 20 (18.9) |
| Naproxen | 6 (2.9) | 8 (3.9) | 3 (1.5) | 0 |
| Acetylsalicylic acid | 13 (6.3) | 14 (6.8) | 8 (3.9) | 7 (6.6) |
| *There were no significant differences among treatment groups. †Nonsteroidal anti‐inflammatory drug (NSAID) use values are for the randomized patient population: olmesartan medoxomil, n=207; losartan potassium, n=207; valsartan, n=203; placebo, n=106. SeSBP indicates seated cuff systolic blood pressure; SeDBP, seated cuff diastolic blood pressure; and HTN, hypertension. | ||||